<DOC>
	<DOC>NCT00216255</DOC>
	<brief_summary>The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.</brief_summary>
	<brief_title>EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study</brief_title>
	<detailed_description />
	<mesh_term>Stuttering</mesh_term>
	<criteria>PDS defined as DSMIVTR criteria, symptoms starting before age 8, and a total overall score of 1836 on the SSI3 Englishspeaking, with 8th grade education, able to understand and cooperate with study requirements without assistance Not pregnant or breastfeeding Able to consent No diagnoses of other CNS/Mental health disorders in the last 6 months No use of psychotropic medication or other medication for stuttering within 4 weeks prior to screening No use of nonmedicinal stuttering treatments for 5 months prior to the study No use of illicit drugs or opiates of any kind</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Persistent Developmental Stuttering</keyword>
</DOC>